Oligometastatic lung cancer
My deployment is limited to a few locations. Are local measures still being discussed?
When spread is limited to a few locations, discussions may include local therapy targeted at the lesion, often in conjunction with systemic therapy.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
What changes at this stage
- The number and location of lesions determine whether a local approach is considered.
- The choice of treatment depends on the size of the lesion and the distance from important structures.
- Response to systemic therapy influences subsequent decisions.
Options that are usually discussed
Stereotactic radiotherapy to limited lesions
SBRT or SRS may be discussed when the lesions are limited in size and few in number.
Systemic therapy with targeted local action
A combination of both is discussed in some patients with limited disease.
Regular monitoring
Periodic imaging is used to assess whether new lesions appear.
The decision remains with your doctor
Practical next steps
- Ask how many lesions were assessed and why.
- Discuss whether local treatment of a particular lesion is beneficial.
- Make sure the follow-up imaging schedule is clear.
Questions for your oncologist
- Is my disease oligometastatic?
- Is local treatment of certain lesions worth considering?
- What is the plan if new lesions appear?
- Are there clinical trials for this group?
Treatment categories
Clinical trials
Registry studies for this group
International-patient access and site readiness have not been verified for any study.
NCT03191149Phase 2Targeted therapy
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Lung Cancer | biomarker: EGFR | Targeted therapy
United States347 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT03191149Not verified
NCT03460977Phase 1Combination regimen
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
United States, Bulgaria, China +584 registry sites
Why this appears: Appears because it is recorded for Lung Cancer.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT03460977Not verified
NCT04267848Phase 3Immunotherapy
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Cancer | Immunotherapy, Chemotherapy
United States, Guam1151 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04267848Not verified
NCT05636969Not applicableCombination regimen
Multimodal Prehabilitation in Patients With Lung Cancer Undergoing Neoadjuvant Therapy
Spain1 registry sites
Why this appears: Appears because it is recorded for Lung Cancer.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05636969Not verified
Would you like to discuss this situation with someone?
Send a request with the context from this page so the documents and questions to prepare can be identified sooner.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- ALK
Biomarker
Reason: Related through a biomarker
- EGFR
Biomarker
Reason: Related through a biomarker
- Lung Cancer
Cancer type
Reason: Has a decision situation
- Metastatic lung cancer
Decision situation
Reason: Mendahului
- Lung cancer progression after targeted therapy
Decision situation
Reason: Mendahului
- Understanding clinical trials: terms, phases, and how to check early fit
Guide
Reason: Related to this page
To check
- Immunotherapy
Treatment category
Reason: Mungkin memerlukan
- Precision radiotherapy (IMRT and VMAT)
Treatment category
Reason: Mungkin memerlukan
- SBRT (stereotactic radiotherapy)
Treatment category
Reason: Mungkin memerlukan
- SRS (intracranial stereotactic radiotherapy)
Treatment category
Reason: Mungkin memerlukan
- Targeted therapy
Treatment category
Reason: Mungkin memerlukan
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.